VANCOUVER, British Columbia and BOSTON, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced equity inducement grants to six new non-officer employees consisting of an aggregate of 24,200 share options. All of the foregoing share options were approved by the Compensation Committee of the Company’s Board of Directors with an effective date of July 31, 2025 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
Global medical cannabis market to hit USD 68.6 billion by 2033, growing at a 7.1% CAGR. Key growth drivers include increasing legalization and therapeutic use for conditions like chronic pain and epilepsy. North America leads due to progressive regulations. Top players like Canopy Growth and GW Pharmaceuticals drive innovation in the sector.
Global medical cannabis market to hit USD 68.6 billion by 2033, growing at a 7.1% CAGR. Key growth drivers include increasing legalization and therapeutic use for conditions like chronic pain and epilepsy. North America leads due to progressive regulations. Top players like Canopy Growth and GW Pharmaceuticals drive innovation in the sector.